BiotechTube

CD19-CAR-T cells

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
25
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

B-cell Malignancy

Conditions

B-cell Malignancy

Trial Timeline

Aug 1, 2019 โ†’ Mar 31, 2021

NCT ID
NCT03952923

About CD19-CAR-T cells

CD19-CAR-T cells is a phase 1 stage product being developed by Avalon GloboCare for B-cell Malignancy. The current trial status is completed. This product is registered under clinical trial identifier NCT03952923. Target conditions include B-cell Malignancy.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03952923Phase 1Completed

Competing Products

20 competing products in B-cell Malignancy

See all competitors
ProductCompanyStageHype Score
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
51
Sepantronium BromideCothera BiosciencePhase 2
44
rituximabCelltrionPhase 1
33
Valemetostat tosylateDaiichi SankyoPhase 2
52
ASP2802 + MA-20Astellas PharmaPhase 1
33
ONTAK (denileukin diftitox)EisaiPhase 2
52
TazemetostatEisaiPhase 2
52
TazemetostatEisaiPhase 1
33
ME-401Kyowa KirinPhase 1
33
ME-401Kyowa KirinPhase 2
52
LOXO-338 + PirtobrutinibEli LillyPhase 1
33
PirtobrutinibEli LillyPre-clinical
23
Rituximab + GemcitabineEli LillyPhase 2
52
IbrutinibJohnson & JohnsonApproved
85
Ibrutinib 420 mg + Ibrutinib 560 mgJohnson & JohnsonApproved
85
ACALABRUTINIB + LISOCABTAGENE MARALEUCEL + Lymphodepleting chemotherapyJohnson & JohnsonPhase 2
52
VELCADE + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + VincristineJohnson & JohnsonPhase 2
52
IbrutinibJohnson & JohnsonPre-clinical
23
SHR1459 tablet + Efavirenz tabletJiangsu Hengrui MedicinePhase 1
33
SHR1459 ๏ผ›YY-20394 + SHR1459 ๏ผ›YY-20394 + Gemcitabine-OxaliplatinJiangsu Hengrui MedicinePhase 2
52